American Bio Medica Corporation manufactures and markets accurate, cost-effective immunoassay test kits, primarily point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC’s Rapid Drug Screen®, Rapid ONE®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® II test for the presence or absence of drugs of abuse in urine, while OralStat® tests for the presence or absence of drugs of abuse in oral fluids. ABMC’s Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.
Company profile
Ticker
ABMC
Exchange
Website
CEO
Melissa A. Waterhouse
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
141702188
ABMC stock data
Latest filings (excl ownership)
10-Q
2023 Q1
Quarterly report
12 Jun 23
NT 10-Q
Notice of late quarterly filing
15 May 23
10-K
2022 FY
Annual report
21 Mar 23
8-K
Completion of Acquisition or Disposition of Assets
1 Mar 23
8-K
Submission of Matters to a Vote of Security Holders
17 Feb 23
UPLOAD
Letter from SEC
13 Jan 23
DEF 14A
Definitive proxy
11 Jan 23
PRER14A
Preliminary revised proxy
5 Jan 23
CORRESP
Correspondence with SEC
5 Jan 23
UPLOAD
Letter from SEC
3 Jan 23
Latest ownership filings
Financial summary
Quarter (USD) | Mar 23 | Dec 22 | Sep 22 | Jun 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 68.00 k | 68.00 k | 68.00 k | 68.00 k | 68.00 k | 68.00 k |
Cash burn (monthly) | (no burn) | (no burn) | (no burn) | (no burn) | 121.00 k | 93.17 k |
Cash used (since last report) | n/a | n/a | n/a | n/a | 1.44 mm | 1.11 mm |
Cash remaining | n/a | n/a | n/a | n/a | -1.37 mm | -1.04 mm |
Runway (months of cash) | n/a | n/a | n/a | n/a | -11.4 | -11.2 |
Institutional ownership, Q1 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|